Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2024-08-27 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2024. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the half-year period. It also includes company business descriptions, shareholder information, and notes on asset pledges and restrictions. The document is over 5,000 characters and contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
第六届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th meeting of the 6th Board of Directors of Beijing Northland Biotech Co., Ltd. It details the meeting date, attendance, and voting results on several agenda items, including approval of the 2024 semi-annual report and a special report on the use of raised funds. It also mentions the establishment of a Shanghai branch. The document does not contain the actual semi-annual report or financial statements but refers to them being published elsewhere. The content focuses on board decisions and meeting resolutions, which fits the category of Board/Management Information (MANG). The document length is short (1712 characters), and it is an announcement of board meeting resolutions rather than the report itself.
2024-08-27 Chinese
关于重组人肝细胞生长因子裸质粒注射液治疗Rutherford 4级（静息痛）严重下肢缺血性疾病Ⅲ期临床试验揭盲结果的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Northland Biotech Co., Ltd. regarding the unblinding results of a Phase III clinical trial for a gene therapy drug. It provides preliminary data analysis results, safety information, and future steps for the drug development. The document explicitly states it is an announcement of clinical trial results and does not contain comprehensive financial data or detailed financial statements. It is not an annual or interim report, nor a regulatory filing about financials. The document is relatively short (1281 characters) and focuses on clinical trial results and their impact on the company, which is typical for a Regulatory Filing (RNS) as it is a general regulatory announcement about clinical progress and risk disclosure. Therefore, the best classification is Regulatory Filings (RNS).
2024-08-15 Chinese
关于完成工商变更登记及公司章程备案并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Northland Biotechnology Co., Ltd. regarding the completion of industrial and commercial registration changes, company charter filing, and obtaining a new business license. It references board and shareholder meetings where related resolutions were passed, but the document itself is a formal notice of these administrative changes and the updated business license details. It does not contain financial statements, audit information, or detailed management reports. The document length is short (1018 characters) and it serves as a formal announcement of corporate registration updates rather than a full report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous official announcements that do not fit other specific categories.
2024-07-17 Chinese
关于在研产品注册上市许可申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a registration application for a product by the National Medical Products Administration (国家药品监督管理局). It discusses the status of an in-development product's regulatory approval process and its potential impact on the company. The document is short (762 characters) and serves as a formal notification rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a product registration acceptance, which does not fit other more specific categories.
2024-07-14 Chinese
关于投资者关系活动记录表的公告
Regulatory Filings Classification · 90% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details a specific investor relations event including the date, participants, and Q&A about clinical trial progress, regulatory submission, and facility construction. There is no financial data, no formal report or earnings release, and no mention of voting results or management changes. The content is a record of an investor relations meeting or activity, not a formal presentation or transcript of a call. Given the nature of the document as a record of investor relations activities, it best fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-07-03 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.